Advertisement

 

 

Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery.

Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery.
Author Information (click to view)

Oh TK, Jeon JH, Lee JM, Kim MS, Kim JH, Cho H, Kim SE, Eom W,


Oh TK, Jeon JH, Lee JM, Kim MS, Kim JH, Cho H, Kim SE, Eom W, (click to view)

Oh TK, Jeon JH, Lee JM, Kim MS, Kim JH, Cho H, Kim SE, Eom W,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2017 07 2112(7) e0181672 doi 10.1371/journal.pone.0181672
Abstract

Opioids are commonly used for postoperative pain control in cancer patients. In addition to pain control, an association between opioid use and long-term oncologic outcomes, such as recurrence or overall survival, has been postulated. The aim of this study was to determine whether postoperative opioid use in patients with non-small cell lung cancer is associated with long-term oncologic outcomes, including recurrence and death. Data obtained from 1009 medical records of patients who underwent curative resection at the National Cancer Center, Korea between January 2006 and December 2010 were retrospectively analyzed. Seven-day opioid use was divided into four quartiles to analyze probability of recurrence and death. Multivariate regression analyses of recurrence and death was conducted, including the calculation of odds ratios. A total of 871 patients were analyzed. When opioid dosage was examined by quartiles, the probability of death and recurrence increased gradually with increasing opioid use. However, in the multivariate regression analysis, the amount of opioid usage did not affect the risk of recurrence or death of lung cancer (P = 0.520 for recurrence; P = 0.659 for death). Opioid use was correlated with outcome when stratified by lung cancer stage (P = 0.004 for recurrence; P = 0.049 for death); however, the odds ratios only slightly increased (1.001 for stage IA-IIIA) for both outcomes. In non-small cell lung cancer patients, the amount of opioid usage does not affect the risk of recurrence and death of lung cancer. There was an association with stage (IA-IIIA), but the effect was negligible. A well-designed prospective study is needed.

Submit a Comment

Your email address will not be published. Required fields are marked *

8 + eleven =

[ HIDE/SHOW ]